KN1022

CAS No. 205255-11-4

KN1022( —— )

Catalog No. M35326 CAS No. 205255-11-4

KN1022 is an inhibitor of phosphorylation of platelet-derived growth factor (PDGF) receptor with IC50 of 0.26 μM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 153 In Stock
10MG 224 In Stock
25MG 337 In Stock
50MG 462 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    KN1022
  • Note
    Research use only, not for human use.
  • Brief Description
    KN1022 is an inhibitor of phosphorylation of platelet-derived growth factor (PDGF) receptor with IC50 of 0.26 μM.
  • Description
    KN1022 an inhibitor of phosphorylation of platelet-derived growth factor receptor (PDGFR) with IC50 of 0.24 μM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    PDGFR
  • Recptor
    PDGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    205255-11-4
  • Formula Weight
    438.44
  • Molecular Formula
    C21H22N6O5
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O(C)C1=CC=2C(=NC=NC2C=C1OC)N3CCN(C(NC4=CC=C(N(=O)=O)C=C4)=O)CC3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kenji Matsuno, et al. Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 1. Synthesis, structure-activity relationship, and biological effects of a new class of quinazoline derivatives. J Med Chem. 2002 Jul 4;45(14):3057-66.?
molnova catalog
related products
  • PP58

    PP58 is an inhibit of PDGFR, FGFR and Src family.

  • CT52923

    CT52923 is a selective, orally active antagonist of platelet-derived growth factor receptor (PDGFR), functioning as an ATP-competitive inhibitor.

  • Olaratumab

    Olaratumab(IMC-3G3) is a human monoclonal IgG1 antibody against platelet-derived growth factor receptor alpha (PDGFRα), which has antitumor effects and can be used to study advanced soft tissue sarcomas.